In the aforementioned T-ACT study [21], given that collection of new tumor biopsy samples at the time of study enrollment (after progression on prior trastuzumab therapy) was not mandatory, reassessment of HER2 positivity was performed for only 16 out of 44 patients. This evidence concerns the gene ERBB2 and neoplasm.